These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 26058185)

  • 1. [Adapting the dose to the residual concentration of infliximab in cryptogenic inflammatory diseases of the intestines].
    Chanson P; Pariente A
    Rev Prat; 2015 Apr; 65(4):473. PubMed ID: 26058185
    [No Abstract]   [Full Text] [Related]  

  • 2. Drug Level-based Anti-Tumor Necrosis Factor Therapy: Ready for Prime Time?
    Ben-Horin S
    Gastroenterology; 2015 Jun; 148(7):1268-71. PubMed ID: 25921372
    [No Abstract]   [Full Text] [Related]  

  • 3. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease.
    Vande Casteele N; Ferrante M; Van Assche G; Ballet V; Compernolle G; Van Steen K; Simoens S; Rutgeerts P; Gils A; Vermeire S
    Gastroenterology; 2015 Jun; 148(7):1320-9.e3. PubMed ID: 25724455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short article: Switching to a infliximab biosimilar: short-term results of clinical monitoring in patients with inflammatory bowel disease.
    Binkhorst L; Sobels A; Stuyt R; Westerman EM; West RL
    Eur J Gastroenterol Hepatol; 2018 Jul; 30(7):699-703. PubMed ID: 29538037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infliximab: new indication. Ulcerative colitis: caution is needed due to long-term risks.
    Prescrire Int; 2007 Oct; 16(91):194. PubMed ID: 17926832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Editorial: prior response to infliximab and early serum drug concentrations predict effects of adalimumab in ulcerative colitis.
    Hendy P; Hart A
    Aliment Pharmacol Ther; 2015 Jan; 41(1):149. PubMed ID: 25483435
    [No Abstract]   [Full Text] [Related]  

  • 7. Biologics for inflammatory bowel diseases in the Asia-Pacific: can we afford to use them, can we afford not to?
    Gearry RB; Irving PM
    J Gastroenterol Hepatol; 2009 Jul; 24(7):1160-2. PubMed ID: 19682189
    [No Abstract]   [Full Text] [Related]  

  • 8. Is infliximab effective for induction of remission in patients with ulcerative colitis?
    Lichtenstein GR
    Inflamm Bowel Dis; 2001 May; 7(2):89-93. PubMed ID: 11383596
    [No Abstract]   [Full Text] [Related]  

  • 9. Infliximab therapy for ulcerative colitis: many unanswered questions.
    Present DH
    Am J Gastroenterol; 2001 Aug; 96(8):2294-6. PubMed ID: 11513164
    [No Abstract]   [Full Text] [Related]  

  • 10. Accelerated infliximab infusions are safe and well tolerated in patients with inflammatory bowel disease.
    Clare DF; Alexander FC; Mike S; Dan G; Allan F; Lisa W; Peter HJ
    Eur J Gastroenterol Hepatol; 2009 Jan; 21(1):71-5. PubMed ID: 19060632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting the response to infliximab from trough serum levels.
    Rutgeerts P; Vermeire S; Van Assche G
    Gut; 2010 Jan; 59(1):7-8. PubMed ID: 20007955
    [No Abstract]   [Full Text] [Related]  

  • 12. Comment on 'Predicting the response to infliximab from trough serum levels'.
    Bendtzen K; Steenholdt C; Ainsworth M; Thomsen OØ; Brynskov J
    Gut; 2010 Sep; 59(9):1298-9; author reply 1299-300. PubMed ID: 20801776
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical remission after stopping infliximab in Crohn's disease: is all that glitters true gold?
    Sorrentino D; Radford-Smith G
    Gastroenterology; 2012 May; 142(5):e17; author reply e18. PubMed ID: 22453047
    [No Abstract]   [Full Text] [Related]  

  • 14. [Case of ulcerative colitis refractory to intravenous cyclosporine therapy successfully treated with infliximab].
    Tsuya R; Motoya S; Tanaka H; Nakagaki S; Nishioka H; Hagiwara T; Kozawa H; Kurokawa S; Ambo T; Imamura A
    Nihon Shokakibyo Gakkai Zasshi; 2008 May; 105(5):679-85. PubMed ID: 18460856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Usefulness of therapeutic monitoring of infliximab in the treatment of inflammatory bowel disease].
    Quera R; Moreno M; Simian D; Ibáñez P; Lubascher J; Figueroa C; Flores L; Kronberg U; Pizarro G; Fluxá D
    Rev Med Chil; 2018 Nov; 146(11):1241-1251. PubMed ID: 30725037
    [No Abstract]   [Full Text] [Related]  

  • 16. Nanotherapeutics for the treatment of inflammatory bowel disease.
    Chen Q; Xiao B; Merlin D
    Expert Rev Gastroenterol Hepatol; 2017 Jun; 11(6):495-497. PubMed ID: 28317404
    [No Abstract]   [Full Text] [Related]  

  • 17. [Biological therapy in children with inflammatory bowel syndrome (clinical cases)].
    Alieva ÉI
    Eksp Klin Gastroenterol; 2014; (1):110-2. PubMed ID: 25518466
    [No Abstract]   [Full Text] [Related]  

  • 18. Preventing antibodies to infliximab in patients with Crohn's disease: optimize not immunize.
    Sandborn WJ
    Gastroenterology; 2003 Apr; 124(4):1140-5. PubMed ID: 12671907
    [No Abstract]   [Full Text] [Related]  

  • 19. Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study.
    Jahnsen J; Detlie TE; Vatn S; Ricanek P
    Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():45-52. PubMed ID: 26395534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TPMT Testing Before Starting Azathioprine or Mercaptopurine: Surely Just Do It?
    Sanderson JD
    Gastroenterology; 2015 Oct; 149(4):850-3. PubMed ID: 26311276
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.